Publication

Immunomodulatory effects and protection of moxifloxacin in sepsis

View document

Bibliographic Details
Summary:Sepsis is a complex syndrome that results from a harmful systemic inflammatory response to infection. It is the leading cause of death in Intensive Care Units, excluding neurotrauma, and the third most important cause of death in the hospital. However, it remains poorly understood, and in fact, in the past decades there have been no substantial advances in the treatment of this condition. As TNF-α and IL-1β are two important initial mediators of sepsis, immunomodulatory agents may be useful in the treatment of sepsis. Here we show that moxifloxacin, a fourth-generation fluoroquinolone with a broad antibacterial spectrum, has immunodulatory effects both in an in vitro assay and in a mice model of sepsis. Moxifloxacin protects against severe sepsis in mice, reducing the levels of cytokines and organ lesion markers. Moreover, our findings demonstrate that its actions are not due to its antibacterial effect and that its interaction with topoisomerase II or IV may not be relevant for the observed effects. The molecular mechanisms that explain its immunomodulatory effects remain unknown, and are certainly an interesting topic for future studies.
Main Authors:Velho, Tiago Rodrigues
Subject:IL-1β TNF-α Sepsis Moxifloxacin
Year:2014
Country:Portugal
Document type:master thesis
Access type:restricted access
Associated institution:Universidade de Lisboa
Language:English
Origin:Repositório da Universidade de Lisboa

Similar Items

Funded activities

No funded projects found.

Similar Items